Fibrocell Science, Inc. Autologous Fibroblast Injections Show Improvement in Facial Acne Scar Appearance
4/15/2013 12:16:35 PM
EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTC: FCSC) today announced that its Phase 2 study to evaluate the safety and efficacy of azficel-T (LAVIV®) for the treatment of patients with moderate-to-severe acne scars has been accepted for publication in Dermatologic Surgery, the peer-reviewed journal of the American Society for Dermatologic Surgery. The findings demonstrated that azficel-T treatment was associated with clinically meaningful improvement in acne scar appearance and was judged safe and superior to control treatment. The Early View (Online Version of Record) of the article is available at http://onlinelibrary.wiley.com/doi/10.1111/dsu.12204/pdf.
comments powered by